FeesSafety
Pluang+

Paladin Energy posts strong Q1 FY27 results despite uranium price drop, with improved margins and solid sales.

Market News
29 Oct 2026, 12:33 WIB
Seeking Alpha
View Source
Neutral
Paladin Energy posts strong Q1 FY27 results despite uranium price drop, with improved margins and solid sales.

Paladin Energy reported solid Q1 FY27 results despite a significant drop in uranium prices, with production declines due to planned maintenance rather than operational issues. Sales volumes and realized uranium prices increased year-over-year, leading to an estimated gross margin improvement to 20.4% from a loss last year. The stock trades at a forward price-to-sales ratio of 5.4x, lower than peers, indicating potential upside if market sentiment improves. The analyst assigns a Hold rating, citing sector momentum and macroeconomic risks, but sees no long-term issues and will watch for better market conditions.

Paladin Energy's recent stock update provides context for readers interested in the Basic Materials sector. As of Oct 29, 2026 16:01 WIB, out of 83 priced US Basic Materials stocks on Pluang, 22 rose and 58 fell. Notable movers include MP Materials at USD 40.00 with a 1-day change of -2.58%, Linde PLC at USD 521.16 with a 1-day change of +2.56%, and SSR Mining Inc. at USD 28.94 with a 1-day change of -2.49%.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
15 minutes ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
15 minutes ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
1 hour ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
1 hour ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App